In a recent study entitled “Difficulties in diagnosis of systemic sclerosis-related interstitial lung disease”, researchers present a case-report of a Caucasian woman and highlight the difficulties in identifying and diagnosing systemic sclerosis-associated with interstitial lung disease. The study was published in the Respirology Case Reports…
News
A new study recently published in the journal BMC Musculoskeletal Disorders revealed that patients with systemic sclerosis have a reduced incidence of Crohn’s disease in comparison to the general population. The study was performed by a team of researchers at several universities in Taiwan, and is entitled…
In a newly published paper in PLOS one journal entitled “Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis,” researchers from University of Foggia in Italy investigated if skin sclerosis (SSc) could…
In a recent study published in the journal Arthritis & Rheumatology, entitled, “Pulmonary Function Tests: High Rate of False Negatives in the Early Detection and Screening of Scleroderma Interstitial Lung Disease,” a team of researchers from the University Hospital Zurich led by…
Top-line results from the Apricus Biosciences, Inc. Phase 2a clinical trial for RayVa™ topical treatment in patients with scleroderma-related Raynaud’s phenomenon indicate the treatment is safe and effective. Patients tolerated treatment and reported a noticeable change in the way their skin temperature responded to a cold challenge. There are…
Preliminary results for the Phase 2 LARIAT clinical trial conducted by Reata Pharmaceuticals for bardoxolone methyl in pulmonary arterial hypertension will be presented at the upcoming 2015 American College of Chest Physicians (CHEST) annual meeting in Montreal, Canada. Ronald Oudiz, MD, Professor of Medicine in David Geffen School of Medicine…
Cytori’s Cell Therapy Offers Long-Term Benefits for Scleroderma Patients with Impaired Hand Function
Late stage cell therapy developer Cytori Therapeutics, a company creating autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently published its findings from a 12-month clinical follow-up of scleroderma patients who were enrolled in the Scleradec-I clinical trial on hand dysfunction associated with the disease. The Scleradec-I study, an…
Researchers Use Tear Samples of Scleroderma Patients To Gain New Insights Into How SSc Affects Eyes
A study was recently conducted to determine levels of vascular endothelial growth factor in the tears of patients with scleroderma. Vascular endothelial growth factor or VEGF has been found to play a major role in the development of new blood vessels in a number of diseases, including macular degeneration of the eye, diabetic…
In a recent study published in Fibrogenesis & Tissue Repair entitled “Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1,” scientists from Medical University of South Carolina reported new insights into the mechanism of…
Corbus Pharmaceuticals Initiates Phase 2 Study Patient Enrollment of Resunab for Systemic Sclerosis
Corbus Pharmaceuticals Holdings, Inc. a clinical stage drug development company targeting chronic, rare, and serious inflammatory and fibrotic diseases with clear unmet needs, recently announced the initiation of patient enrollment for its Phase 2 trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Systemic Sclerosis (Scleroderma) is a…
Recent Posts
- Off-the-shelf cell therapy shows early promise as scleroderma treatment
- Trial to test scleroderma treatments at earliest stages of disease
- Off-label JAK inhibitors may stabilize lung function in systemic sclerosis
- Distinct symptom pattern found for triple-negative scleroderma patients
- Plant-based nanoparticle therapy eases skin thickening in SSc: Study
- Specialized MRI scans may catch early lung damage in scleroderma
- Spotlighting ‘Beacons of Hope’ for this year’s Scleroderma Awareness Month
- Fewer capillaries in hands may contribute to scleroderma bone loss
- New scleroderma therapy BLR-200 shows potential to prevent scarring
- Signaling pathway in skin cells may drive scleroderma inflammation